$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

$plsh Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016537 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$399.1K	$677.5K	$324.8K
YoY Change	-14.98%	45.24%	-49.72%
Cost Of Revenue	$196.3K	$451.9K	$1.534M
YoY Change	-40.78%	-72.68%	-29.88%
Gross Profit	$202.8K	$225.6K	-$1.209M
YoY Change	47.0%	-119.0%	-21.56%
Gross Profit Margin	50.81%	33.3%	-372.22%
Selling, General & Admin	$145.2K	$247.4K	$166.6K
YoY Change	-29.06%	-46.28%	-72.54%
% of Gross Profit	71.6%	109.66%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$422.7K	$422.6K	$444.8K
YoY Change	3.13%	-0.35%	8.26%
% of Gross Profit	208.43%	187.29%
Operating Expenses	$1.277M	$1.516M	$166.6K
YoY Change	-7.33%	229.08%	-72.54%
Operating Profit	-$1.074M	-$1.290M	-$1.376M
YoY Change	-13.38%	-21.73%	-35.96%
Interest Expense	$366.9K	$380.2K	-$387.1K
YoY Change	-35.62%	-126.29%	135.97%
% of Operating Profit
Other Income/Expense, Net	-$790.1K	-$501.3K	$58.05K
YoY Change	9.47%	-260.77%	-73.8%
Pretax Income	-$1.864M	-$1.791M	-$1.705M
YoY Change	-4.97%	-35.62%	-18.46%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.864M	-$1.791M	-$1.705M
YoY Change	-4.97%	-35.62%	-18.46%
Net Earnings / Revenue	-467.08%	-264.41%	-524.84%
Basic Earnings Per Share	-$0.11	-$0.12
Diluted Earnings Per Share	-$0.11	-$0.12	-$0.11
COMMON SHARES
Basic Shares Outstanding	15.51M shares	14.76M shares	14.97M shares
Diluted Shares Outstanding	17.65M shares	14.97M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$468.6K	$998.3K	$1.114M
YoY Change	-81.97%	-65.61%	-70.76%
Cash & Equivalents	$8.190K	$73.23K	$6.951K
Short-Term Investments	$460.4K	$925.1K	$1.107M
Other Short-Term Assets	$149.3K	$78.55K	$113.1K
YoY Change	-53.37%	-66.38%	-59.36%
Inventory	$4.358M	$4.095M	$4.449M
Prepaid Expenses
Receivables	$272.1K	$274.8K	$206.1K
Other Receivables	$500.0K	$500.0K	$500.0K
Total Short-Term Assets	$5.748M	$5.947M	$6.382M
YoY Change	-29.21%	-26.8%	-29.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.855M	$7.269M	$7.676M
YoY Change	-16.48%	-39.69%	-13.17%
Goodwill	$2.189M	$2.189M	$2.189M
YoY Change	0.0%		0.0%
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$12.11M	$12.61M	$13.11M
YoY Change	-12.57%	-11.73%	-10.75%
TOTAL ASSETS
Total Short-Term Assets	$5.748M	$5.947M	$6.382M
Total Long-Term Assets	$12.11M	$12.61M	$13.11M
Total Assets	$17.85M	$18.56M	$19.49M
YoY Change	-18.72%	-17.19%	-18.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.678M	$3.066M	$2.666M
YoY Change	43.35%	42.53%	58.15%
Accrued Expenses	$592.8K	$2.208M	$2.090M
YoY Change	-68.08%	26.86%	28.7%
Deferred Revenue
YoY Change
Short-Term Debt	$11.04M	$10.62M	$10.32M
YoY Change	27.8%	38.49%	52.6%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.05M	$15.89M	$15.07M
YoY Change	30.49%	37.49%	49.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.573M	$3.573M	$3.573M
YoY Change	2.68%	-46.45%	9.5%
Total Long-Term Liabilities	$3.573M	$3.573M	$3.573M
YoY Change	2.68%	-46.45%	9.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.05M	$15.89M	$15.07M
Total Long-Term Liabilities	$3.573M	$3.573M	$3.573M
Total Liabilities	$23.42M	$22.36M	$21.63M
YoY Change	18.81%	22.65%	29.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.60M	-$27.70M	-$25.90M
YoY Change	37.67%		54.49%
Common Stock	$1.765K	$1.551K	$1.497K
YoY Change	17.9%		6.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.567M	-$3.801M	-$2.145M
YoY Change
Total Liabilities & Shareholders Equity	$17.85M	$18.56M	$19.49M
YoY Change	-18.72%	-17.19%	-18.06%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.864M	-$1.791M	-$1.705M
YoY Change	-4.97%	-35.62%	-18.46%
Depreciation, Depletion And Amortization	$422.7K	$422.6K	$444.8K
YoY Change	3.13%	-0.35%	8.26%
Cash From Operating Activities	-$483.3K	-$313.9K	-$523.0K
YoY Change	-33.74%	-28.02%	-57.48%
INVESTING ACTIVITIES
Capital Expenditures	$9.350K	$15.22K	$98.84K
YoY Change	-218.81%	-256.42%	-160.66%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	-$9.350K	-$15.22K	-$98.84K
YoY Change	-124.0%	56.42%	-1145.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	427.6K	$395.4K	592.0K
YoY Change	-36.27%	-17.98%	-51.7%
NET CHANGE
Cash From Operating Activities	-483.3K	-$313.9K	-523.0K
Cash From Investing Activities	-9.350K	-$15.22K	-98.84K
Cash From Financing Activities	427.6K	$395.4K	592.0K
Net Change In Cash	-65.04K	$66.28K	-29.84K
YoY Change	234.22%	83.0%	-666.22%
FREE CASH FLOW
Cash From Operating Activities	-$483.3K	-$313.9K	-$523.0K
Capital Expenditures	$9.350K	$15.22K	$98.84K
Free Cash Flow	-$492.7K	-$329.1K	-$621.8K
YoY Change	-31.72%	-22.81%	-41.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001552189
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	PLSH	Employer Retention Credit EmployerRetentionCredit		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Other Receivable After Allowance For Credit Loss Related And Nonrelated Party Status Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Related And Nonrelated Party Status Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	us-gaap	Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	us-gaap	Other Liability Noncurrent Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityNoncurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Noncurrent Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityNoncurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2022Q1	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2023Q1	PLSH	Non Cash Settlement Of Convertible Note And Accrued Interest NonCashSettlementOfConvertibleNoteAndAccruedInterest		usd
CY2022Q1	PLSH	Non Cash Settlement Of Convertible Note And Accrued Interest NonCashSettlementOfConvertibleNoteAndAccruedInterest		usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2023Q1	PLSH	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt		usd
CY2022Q1	PLSH	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt		usd
CY2023Q1	us-gaap	Proceeds From Previous Acquisition ProceedsFromPreviousAcquisition		usd
CY2022Q1	us-gaap	Proceeds From Previous Acquisition ProceedsFromPreviousAcquisition		usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022Q1	PLSH	Repayment Of Notes Payable RepaymentOfNotesPayable		usd
CY2023Q1	PLSH	Proceeds From Payroll Protection Sba Loans ProceedsFromPayrollProtectionSBALoans		usd
CY2022Q1	PLSH	Proceeds From Payroll Protection Sba Loans ProceedsFromPayrollProtectionSBALoans		usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	PLSH	Noncash Receivable Related Party NoncashReceivableRelatedParty		usd
CY2022Q1	PLSH	Noncash Receivable Related Party NoncashReceivableRelatedParty		usd
CY2023Q1	PLSH	Noncash Related Party Loan Repayment With Inventory NoncashRelatedPartyLoanRepaymentWithInventory		usd
CY2022Q1	PLSH	Noncash Related Party Loan Repayment With Inventory NoncashRelatedPartyLoanRepaymentWithInventory		usd
CY2023Q1	PLSH	Noncash Fixed Asset Disposal As Part Of Reverse Acquisition NoncashFixedAssetDisposalAsPartOfReverseAcquisition		usd
CY2022Q1	PLSH	Noncash Fixed Asset Disposal As Part Of Reverse Acquisition NoncashFixedAssetDisposalAsPartOfReverseAcquisition		usd
CY2023Q1	PLSH	Conversion Of Preferred Shares To Note Payable ConversionOfPreferredSharesToNotePayable		usd
CY2023Q1	PLSH	Issuance Of Common Stock For Services Non Cash IssuanceOfCommonStockForServicesNonCash		usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2023Q1	PLSH	Liabilities From Acquisition Non Cash LiabilitiesFromAcquisitionNonCash		usd
CY2022Q1	PLSH	Liabilities From Acquisition Non Cash LiabilitiesFromAcquisitionNonCash		usd
CY2023Q1	us-gaap	Notes Reduction NotesReduction		usd
CY2022Q1	us-gaap	Notes Reduction NotesReduction		usd
CY2023Q1	PLSH	Preferred Stock Series B One Non Cash PreferredStockSeriesBOneNonCash		usd
CY2022Q1	PLSH	Preferred Stock Series B One Non Cash PreferredStockSeriesBOneNonCash		usd
CY2023Q1	PLSH	Preferred Stock Series B Two Non Cash PreferredStockSeriesBTwoNonCash		usd
CY2022Q1	PLSH	Preferred Stock Series B Two Non Cash PreferredStockSeriesBTwoNonCash		usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q1	PLSH	Discounts Related To Issuance Of Convertible Debt And Warrants DiscountsRelatedToIssuanceOfConvertibleDebtAndWarrants		usd
CY2022Q1	PLSH	Discounts Related To Issuance Of Convertible Debt And Warrants DiscountsRelatedToIssuanceOfConvertibleDebtAndWarrants		usd
CY2022Q4	PLSH	Trading Goods TradingGoods		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3066135	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2666076	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2022Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
CY2023Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
CY2023Q1	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2023Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Vested And Exercisable In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionVestedAndExercisableInPeriodWeightedAverageIntrinsicValue		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38190
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Panacea Life Sciences Holdings, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1085858
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5910 S University Blvd
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	C18-193
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Greenwood Village
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80121
CY2023Q1	dei	City Area Code CityAreaCode	800
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	985-0515
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15505317	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73232	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6951	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	274787	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	206127	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	500000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	500000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	4095063	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4448725	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	925107	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1107362	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	78546	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113098	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	5946735	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2208025	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2090271	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6382263	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3152570	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3242381	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7268661	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7675995	usd
CY2023Q1	us-gaap	Goodwill Goodwill	2188810	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2188810	usd
CY2023Q1	us-gaap	Assets Assets	18556776	usd
CY2022Q4	us-gaap	Assets Assets	19489449	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1289963	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	10402155	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9871803	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	115000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	346671	usd
CY2023Q1	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2022Q4	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15890415	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15073921	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2894336	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2987208	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2023Q1	us-gaap	Liabilities Liabilities	22357615	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21633993	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15505317	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15505317	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14965317	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14965317	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1551	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1497	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23895650	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23760704	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27698892	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25907597	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3800839	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18556776	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19489449	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	677481	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	466474	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	451872	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	366091	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	225609	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	100383	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1268159	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1287817	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	247413	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	460550	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1515572	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1748367	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1647984	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	380157	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	501295	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-182255	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-944804	usd
CY2022Q1	PLSH	Employer Retention Credit EmployerRetentionCredit	253791	usd
CY2023Q1	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	60332	usd
CY2022Q1	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	58046	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	748	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-501332	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1134262	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1791295	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2782246	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1791295	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2782246	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14862077	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16915706	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	135000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1791295	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3800839	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7102402	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-159362	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2782246	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4180794	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1791295	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2782246	usd
CY2023Q1	us-gaap	Depreciation Depreciation	422554	usd
CY2022Q1	us-gaap	Depreciation Depreciation	408691	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-182255	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-944804	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15350	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	38329	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	263270	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	68660	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-81878	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-353662	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	60510	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-34552	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-44715	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	400059	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	533311	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	114693	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	114694	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-313851	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-436043	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15220	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9725	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15220	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9725	usd
CY2023Q1	PLSH	Repayment Of Notes Payable RepaymentOfNotesPayable	135000	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	65000	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	230201	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	595352	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	712192	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	395352	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	481991	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66281	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36223	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6951	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19774	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73232	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	55997	usd
CY2022Q1	PLSH	Conversion Of Preferred Shares To Note Payable ConversionOfPreferredSharesToNotePayable	385000	usd
CY2022Q1	PLSH	Issuance Of Common Stock For Services Non Cash IssuanceOfCommonStockForServicesNonCash	20000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	102344	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27700000	usd
CY2023Q1	PLSH	Cash And Liquid Stock CashAndLiquidStock	1000000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_z3KQpc5QhjK7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span><span id="xdx_86A_zpRdyfXrigve">Use of Estimates</span></span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with US GAAP and required management of the Company to make estimates and assumptions in preparation of these statements. Actual results may differ significantly from those estimates. Significant estimates made by management include but are not limited to the useful life of property and equipment, incremental borrowing rate used in the calculation of right of use asset and lease liability, reserves for inventory, allowance for doubtful accounts, revenue allocations, valuation allowance on deferred tax assets, assumptions used in assessing impairment of long-term assets, assumptions used in the calculation of net realizable value of inventory and fair value of non-cash equity transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1378	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	368065	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	925107	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1107362	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1107362	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-182255	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	925107	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	24585	usd
CY2023Q1	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	178586	usd
CY2022	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	412891	usd
CY2023Q1	PLSH	Revenue Earned Amount RevenueEarnedAmount	292169	usd
CY2022	PLSH	Revenue Earned Amount RevenueEarnedAmount	69411	usd
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2023Q1	us-gaap	Goodwill Goodwill	2188810	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2188810	usd
CY2023Q1	PLSH	Customer Advances Payments CustomerAdvancesPayments	254482	usd
CY2022Q4	PLSH	Customer Advances Payments CustomerAdvancesPayments	368065	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	254482	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	368065	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5015719	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5015719	shares
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13214093	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13198873	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5945432	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5522878	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7268661	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7675995	usd
CY2023Q1	us-gaap	Depreciation Depreciation	422554	usd
CY2022Q1	us-gaap	Depreciation Depreciation	408691	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	720557	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	870530	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1737215	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1863501	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1617341	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1694574	usd
CY2023Q1	PLSH	Packaging Supplies PackagingSupplies	19950	usd
CY2022Q4	PLSH	Packaging Supplies PackagingSupplies	20120	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	4095063	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4448725	usd
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3152570	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3242381	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3258312	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3347331	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2894336	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2987208	usd
CY2023Q1	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	363976	usd
CY2022Q4	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	360123	usd
CY2023Q1	PLSH	Unpaid Balance UnpaidBalance	1844042	usd
CY2022Q4	PLSH	Unpaid Balance UnpaidBalance	1730136	usd
CY2023Q1	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	2208018	usd
CY2022Q4	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	2090259	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030	pure
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	114693	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	114693	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	341716	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	460178	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	464780	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	469427	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	474122	usd
CY2023Q1	PLSH	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1451002	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3661225	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	402913	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3258312	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	540000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	196491	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.51
CY2023Q1	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P3Y2M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	196491	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.51
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y11M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	196491	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.51
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y11M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	331377	shares
CY2022Q4	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	3.48
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y8M1D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	331377	shares
CY2023Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	3.48
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y5M4D
CY2023Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	331377	shares
CY2023Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice	3.48
CY2023Q1	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y5M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	107993	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	107993	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001

Files In Submission

Name	View Source	Status
0001493152-23-016537-index-headers.html	Edgar Link	pending
0001493152-23-016537-index.html	Edgar Link	pending
0001493152-23-016537.txt	Edgar Link	pending
0001493152-23-016537-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plsh-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
plsh-20230331_def.xml	Edgar Link	unprocessable
plsh-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
plsh-20230331_lab.xml	Edgar Link	unprocessable
plsh-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

2023 Q2 Form 10-Q Financial Statement

#000149315223016537 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH Panacea Life Sciences Holdings Inc Stock $plsh

2023 Q2 Form 10-Q Financial Statement

#000149315223016537 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh